Key Points
- EVP Shannon Devers sold 16,777 shares on Nov. 25 at an average price of $80.91 for about $1.36M, reducing her stake by 48.95% to 17,494 shares, per an SEC filing.
- Ionis beat Q3 estimates with EPS of ($0.80) vs. ($1.15) expected and revenue of $156.72M (up 17.2% YoY), but remains unprofitable and analysts project roughly -$3.5 EPS for the fiscal year.
- Analyst sentiment is broadly positive—several firms raised price targets (TD Cowen to $99) and MarketBeat shows a Moderate Buy consensus with a $84.15 target—while the stock trades near its 12‑month high (~$82.75) and a $13.4B market cap.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Shannon Devers sold 16,777 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $80.91, for a total value of $1,357,427.07. Following the transaction, the executive vice president directly owned 17,494 shares of the company's stock, valued at $1,415,439.54. The trade was a 48.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Ionis Pharmaceuticals Trading Up 0.1%
Shares of Ionis Pharmaceuticals stock opened at $82.75 on Friday. The company's 50-day moving average price is $71.72 and its 200-day moving average price is $52.72. The company has a current ratio of 2.87, a quick ratio of 2.86 and a debt-to-equity ratio of 0.99. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $82.95. The company has a market cap of $13.40 billion, a price-to-earnings ratio of -48.96 and a beta of 0.33.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 45.29%. The business had revenue of $156.72 million for the quarter, compared to analyst estimates of $131.75 million. During the same quarter in the prior year, the firm posted ($0.95) EPS. Ionis Pharmaceuticals's revenue was up 17.2% on a year-over-year basis. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently commented on IONS. TD Cowen boosted their target price on Ionis Pharmaceuticals from $59.00 to $99.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. BMO Capital Markets raised shares of Ionis Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $40.00 to $70.00 in a research note on Wednesday, September 3rd. Stifel Nicolaus upped their price objective on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a "hold" rating in a report on Monday, October 6th. Piper Sandler upped their price target on Ionis Pharmaceuticals from $70.00 to $77.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 4th. Finally, Oppenheimer increased their price target on shares of Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $84.15.
View Our Latest Analysis on IONS
Hedge Funds Weigh In On Ionis Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of IONS. BlueCrest Capital Management Ltd purchased a new stake in shares of Ionis Pharmaceuticals during the third quarter worth about $1,529,000. Alpine Global Management LLC grew its position in Ionis Pharmaceuticals by 119.8% in the third quarter. Alpine Global Management LLC now owns 55,900 shares of the company's stock worth $3,657,000 after acquiring an additional 30,463 shares in the last quarter. Tweedy Browne Co LLC increased its position in shares of Ionis Pharmaceuticals by 0.3% during the 3rd quarter. Tweedy Browne Co LLC now owns 2,901,216 shares of the company's stock valued at $189,798,000 after purchasing an additional 9,268 shares during the last quarter. Coldstream Capital Management Inc. purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at $293,000. Finally, Danske Bank A S purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at $92,000. 93.86% of the stock is currently owned by hedge funds and other institutional investors.
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
